DrugPatentWatch Database Preview
ANJESO Drug Profile
» See Plans and Pricing
When do Anjeso patents expire, and when can generic versions of Anjeso launch?
Anjeso is a drug marketed by Baudax and is included in one NDA. There are five patents protecting this drug.
This drug has thirty-three patent family members in eleven countries.
The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Anjeso
A generic version of ANJESO was approved as meloxicam by CIPLA on July 19th, 2006.
Summary for ANJESO
| International Patents: | 33 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ANJESO |
| What excipients (inactive ingredients) are in ANJESO? | ANJESO excipients list |
| DailyMed Link: | ANJESO at DailyMed |
US Patents and Regulatory Information for ANJESO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ANJESO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2011042670 | Start Trial |
| European Patent Office | 3090731 | Start Trial |
| Canada | 2763456 | Start Trial |
| Hungary | E040393 | Start Trial |
| Spain | 2701673 | Start Trial |
| Denmark | 3090731 | Start Trial |
| Denmark | 3434261 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
